TY  - JOUR
AU  - Aarsland, Dag
AU  - Sunde, Anita Lenora
AU  - Tovar-Rios, Diego A
AU  - Leuzy, Antoine
AU  - Fladby, Tormod
AU  - Zetterberg, Henrik
AU  - Blennow, Kaj
AU  - Tan, Kübra
AU  - De Santis, Giovanni
AU  - Yakoub, Yara
AU  - Arslan, Burak
AU  - Huber, Hanna
AU  - Pola, Ilaria
AU  - Grötschel, Lana
AU  - Di Molfetta, Guglielmo
AU  - Skjellegrind, Håvard K
AU  - Selbaek, Geir
AU  - Ashton, Nicholas J
TI  - Prevalence of Alzheimer's disease pathology in the community.
JO  - Nature
VL  - 650
IS  - 8100
SN  - 0028-0836
CY  - London [u.a.]
PB  - Nature Publ. Group
M1  - DZNE-2026-00147
SP  - 182 - 186
PY  - 2026
AB  - The prevalence of Alzheimer's disease neuropathological changes (ADNCs), the leading cause of cognitive impairment, remains uncertain. Recent blood-based biomarkers enable scalable assessment of ADNCs1. Here we measured phosphorylated tau at threonine 217 in 11,486 plasma samples from a Norwegian population-based cohort of individuals over 57 years of age as a surrogate marker for ADNCs. The estimated prevalence of ADNCs increased with age, from less than 8
KW  - Humans
KW  - Alzheimer Disease: epidemiology
KW  - Alzheimer Disease: pathology
KW  - Alzheimer Disease: blood
KW  - Alzheimer Disease: diagnosis
KW  - Aged
KW  - Prevalence
KW  - Aged, 80 and over
KW  - Male
KW  - Female
KW  - tau Proteins: blood
KW  - tau Proteins: chemistry
KW  - Norway: epidemiology
KW  - Cognitive Dysfunction: epidemiology
KW  - Cognitive Dysfunction: blood
KW  - Cognitive Dysfunction: pathology
KW  - Middle Aged
KW  - Phosphorylation
KW  - Cohort Studies
KW  - Biomarkers: blood
KW  - Age Factors
KW  - tau Proteins (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41407852
DO  - DOI:10.1038/s41586-025-09841-y
UR  - https://pub.dzne.de/record/285022
ER  -